Genelux (GNLX) Other Working Capital Changes (2022 - 2026)
Genelux's (GNLX) quarterly Other Working Capital Changes came in at -$87000.0 in Q1 2026, down 7.41% year-on-year from -$93960.0 in Q1 2025, and up 6.45% quarter-over-quarter from -$93000.0 in Q4 2025.
Genelux (GNLX) Other Working Capital Changes (2022 - 2026) Analysis & Trends
Genelux's Other Working Capital Changes history runs 5 years deep, the most recent figure standing at -$87000.0 for Q1 2026.
- On a quarterly basis, Other Working Capital Changes fell 7.41% year-over-year to -$87000.0 in Q1 2026; TTM through Mar 2026 was -$343000.0, a 41.27% increase from a year earlier, with the FY2025 full-year figure at -$337000.0, up 48.23% from the prior year.
- Other Working Capital Changes rose to -$87000.0 in Q1 2026 per GNLX's latest filing, from -$93000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $565000.0 in Q1 2024 and bottomed at -$4.5 million in Q4 2022.
- The 5-year median for Other Working Capital Changes is -$47000.0 (2023), against an average of -$389714.3.
- Across the five-year window, Other Working Capital Changes slumped 85.87% in 2024 and jumped 51.22% in 2025, its largest moves.
- Year by year, Other Working Capital Changes stood at -$106000.0 in 2022, then advanced by 13.21% to -$92000.0 in 2023, then slumped by 85.87% to -$171000.0 in 2024, then jumped by 45.61% to -$93000.0 in 2025, then climbed by 6.45% to -$87000.0 in 2026.
- Per Business Quant, the three latest GNLX Other Working Capital Changes figures stand at -$87000.0 (Q1 2026), -$93000.0 (Q4 2025), and -$83000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn |
| 10 | Genelux | 128.70 Mn | 128.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87,000.00 |
| Mar 31, 2026 | -87,000.00 |
| Mar 31, 2026 | -87,000.00 |
| Dec 31, 2025 | -93,000.00 |
| Dec 31, 2025 | -93,000.00 |
| Dec 31, 2025 | -93,000.00 |
| Sep 30, 2025 | -83,000.00 |
| Sep 30, 2025 | -83,000.00 |
| Sep 30, 2025 | -83,000.00 |
| Jun 30, 2025 | -80,000.00 |
| Jun 30, 2025 | -80,000.00 |
| Jun 30, 2025 | -80,000.00 |
| Mar 31, 2025 | -81,000.00 |
| Mar 31, 2025 | -81,000.00 |
| Mar 31, 2025 | -81,000.00 |
| Dec 31, 2024 | -171,000.00 |
| Dec 31, 2024 | -171,000.00 |
| Dec 31, 2024 | -171,000.00 |
| Sep 30, 2024 | -168,000.00 |
| Sep 30, 2024 | -168,000.00 |